Browsing Tag
cancer diagnostics
11 posts
Abbott (ABT) closes $21bn Exact Sciences deal, making it the leader in U.S. cancer screening diagnostics
Abbott (ABT) closes its $21bn Exact Sciences acquisition, creating a $12bn+ diagnostics leader in cancer screening and precision oncology. Read the full analysis.
Exact Sciences stockholders approve Abbott acquisition, clearing final hurdle in $21bn cancer diagnostics deal
Exact Sciences stockholders approve Abbott’s $21 billion acquisition. Find out how the deal could reshape cancer diagnostics and investor strategy.
Exact Sciences (NASDAQ: EXAS) earnings show why Abbott moved now on a $21bn diagnostics acquisition
Exact Sciences delivered record 2025 results ahead of its Abbott acquisition. Find out why cash flow, screening scale, and timing matter now.
U.S. Department of Veterans Affairs awards EsoGuard contract to Lucid Diagnostics
Explore how Lucid Diagnostics’ VA contract validates EsoGuard, shaping investor sentiment, competitive positioning, and nationwide adoption of non-invasive cancer diagnostics.
Abbott expands diagnostics empire with $23bn takeover of cancer-test leader Exact Sciences
Find out how Abbott’s $23B acquisition of Exact Sciences could reshape cancer diagnostics and redefine growth in oncology screening.
Can Median Technologies’ €23.9m boost reshape AI cancer screening in the U.S. and Europe?
Median Technologies raises €23.9M to fund U.S. eyonis® launch and unlock EIB loan access. Read how the capital boost affects its growth outlook.
U.S. healthcare system adds Sectra pathology module to boost cloud-based cancer diagnostics
A major U.S. healthcare provider expands Sectra One Cloud with digital pathology in $8.9M deal. Find out how it advances cancer diagnostics integration.
Cleo Diagnostics (ASX:COV) gains PLCO biobank access to strengthen FDA submission for ovarian cancer test
Cleo Diagnostics secures PLCO biobank access to enhance its ovarian cancer test FDA filing. Find out how this milestone strengthens global regulatory strategy.
VolitionRx’s Nu.Q Cancer Test targets multi-billion-dollar liquid biopsy market
VolitionRx’s Nu.Q Cancer Test is transforming liquid biopsy diagnostics, offering a non-invasive, cost-effective blood test for early cancer detection.
Prostate cancer diagnosis: A breakthrough in non-invasive testing
Prostate cancer is one of the most prevalent cancers affecting men globally, ranking sixth in occurrence after cancers…